A5019111597- Attention Deficit Hyperactivity Disorder
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Functional Brain Connectivity Studies
- Neural and Behavioral Psychology Studies
- Treatment of Major Depression
- Pharmaceutical studies and practices
- Children's Physical and Motor Development
- Cardiovascular Syncope and Autonomic Disorders
- SARS-CoV-2 detection and testing
- Child and Adolescent Psychosocial and Emotional Development
- Heparin-Induced Thrombocytopenia and Thrombosis
- Long-Term Effects of COVID-19
- Neurotransmitter Receptor Influence on Behavior
- Cardiac electrophysiology and arrhythmias
- Behavioral and Psychological Studies
- Cardiac Arrhythmias and Treatments
- Tryptophan and brain disorders
- Respiratory viral infections research
- Bipolar Disorder and Treatment
- Parkinson's Disease Mechanisms and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Electroconvulsive Therapy Studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Musculoskeletal pain and rehabilitation
Eli Lilly (United States)
2005-2012
University of Florida
1990-2005
The University of Texas Southwestern Medical Center
2005
Massachusetts General Hospital
2005
The Ohio State University
2005
Mount Sinai Medical Center
2005
The University of Texas Medical Branch at Galveston
2005
Nebraska Medical Center
2005
Mercy Health
2005
Research Triangle Park Foundation
2000-2002
BackgroundCoronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 high-risk early the course disease.MethodsIn this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, 1:1 ratio, nonhospitalized symptomatic (≤5 days after onset symptoms) at least one risk factor for receive single...
Older patients and those with comorbidities who are infected SARS-CoV-2 may be at increased risk of hospitalization death. Sotrovimab is a neutralizing antibody for the treatment high-risk to prevent COVID-19 progression.To evaluate efficacy adverse events sotrovimab in preventing progression mild moderate severe disease.Randomized clinical trial including 1057 nonhospitalized symptomatic, least 1 factor conducted 57 sites Brazil, Canada, Peru, Spain, US from August 27, 2020, through March...
Inappropriate or excessive medication use is a commonly observed problem among patients with chronic pain. Comparing patients' self-reported drug actual use, this study examines the incidence, nature and magnitude of utilization in selected population pain evaluates reliability patient estimates their own use. The data support clinical observation that tend to underestimate This tendency greater for narcotic analgesics than variety other medications taken women men.
Abstract Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization and death older patients those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody designed to treat such high-risk early the course of disease, thereby preventing Covid-19 progression. Methods In this ongoing, multicenter, double-blind, phase 3 trial, nonhospitalized symptomatic at least one risk factor for progression were randomized (1:1) an intravenous...
Objectives: Atomoxetine (ATX) once daily was compared with placebo (PBO) in adults attention-deficit/hyperactivity disorder (ADHD) at 12 and 24 weeks. Methods: Patients were randomized to PBO (n = 234) or ATX (60-100 mg; n 268) for weeks following a 2-week on-label (40 mg 3 days then 80 mg) slow 7 titration. After weeks, patients rerandomized either titration strategy. Efficacy measures included the Conners' Adult ADHD Rating Scale Total Symptoms score, Clinical Global...
Attention-deficit/hyperactivity disorder (ADHD) is associated with significant impairment in multiple functional domains. This trial evaluated efficacy ADHD symptoms and outcomes young adults treated atomoxetine.Young (18-30 years old) were randomized to 12 weeks of double-blind treatment atomoxetine (n = 220) or placebo 225). The primary measure symptom change was Conners' Adult Rating Scale (CAARS): Investigator-Rated: Screening Version Total Symptoms score adult prompts. Secondary scales...
A transvenous electrode catheter technique was used for direct recording of bipolar sinus node electrograms during postpacing atrial pauses. Multiple repetitive local quiescence validate electrograms. Such pauses with are due to sinoatrial block; without overdrive suppression or improper recording. Eight consecutive patients were prospectively selected on the basis a corrected recovery time greater than 1500 msec diagnostic electrophysiologic evaluation. Six had electrograms; three patterns...
Convenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) early mild/moderate COVID-19.
The relationship between executive function and comorbid diagnoses in ADHD children is examined. One hundred six 7 15 years of age are assessed using the Tower London (TOL), a test function, Kiddie Schedule Affective Disorders Schizophrenia, Present Lifetime Version, diagnostic interview. All met criteria for ADHD. A majority had anxiety disorders, mood or oppositional defiant disorder. Measures on TOL total move score, initiation time, rule violations. Age predictive all three measures as...
Abstract Background COVID-19 disproportionately results in hospitalization and death older patients those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody that binds highly conserved epitope of the SARS-CoV-2 receptor binding domain has an Fc modification increases half-life. retains activity against UK, S. Africa, Brazil, India, New York California variants vitro. Objectives To evaluate efficacy safety treatment sotrovimab high-risk, non-hospitalized...
The primary objectives of this study were to evaluate the pharmacokinetics (PK) and tolerability single multiple doses vortioxetine in children adolescents with a depressive or anxiety disorder provide supportive information for appropriate dosing regimens pediatric clinical trials.This prospective, open-label, multinational, multisite, multiple-dose trial enrolled 48 patients (children adolescents; 1:1 ratio) divided into 8 cohorts (4 adolescent 4 child), each cohort including 6 patients....
In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety lead-in study), the long-term safety and tolerability vortioxetine (5-20 mg/day) were investigated in children adolescents with a DSM-IV-TR™ diagnosis depressive or anxiety disorder United States Germany. The study also was designed to provide data inform dose selection titration future pediatric studies vortioxetine.Safety evaluations included spontaneously reported adverse events (AEs),...
Abstract Importance Older patients and those with underlying comorbidities infected SARS-CoV-2 may be at increased risk of hospitalization death from COVID-19. Sotrovimab is a neutralizing antibody designed for treatment high-risk to prevent COVID-19 progression. Objective To evaluate the efficacy safety sotrovimab in preventing progression mild moderate severe disease. Design Randomized, double-blind, multicenter, placebo-controlled, phase 3 study. Setting 57 centers 5 countries....
Objective: To assess the effects of lisdexamfetamine dimesylate (LDX) on executive function (EF) behaviors in children with attention-deficit/hyperactivity disorder (ADHD). Methods: This observational, open-label, 7-week, dose-optimization study LDX (20–70 mg/day) ADHD evaluated efficacy Rating Scale IV; safety measures included adverse events (AEs). EF was assessed Behavior Inventory Executive Function (BRIEF). Post hoc analyses examined BRIEF scores by sex, subtype, comorbid psychiatric...
Abboud, T. K.; Sarkis, E; Hung, T.; Khoo, S. S.; Varakian, L.; Henriksen, E.; Noueihed, R.; Goebelsmann, U.; Gutsche, Brett B. M.D. Author Information
Background: This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy. Methods: Eligible adults (18–65 years) were assigned monotherapy (escitalopram or venlafaxine extended-release) plus dimesylate-matching placebo during an eight-week single-blind lead-in phase. Participants meeting...
Aim: Sotrovimab is an engineered human monoclonal antibody that binds a conserved region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab for treatment mild to moderate COVID-19 in nonhospitalized participants with ≥1 risk factor severe disease progression. Materials & methods: We presence circulating variants concern or interest (VOCs/VOIs) and characterized baseline, post-baseline emergent amino acid substitutions detected epitope SARS-CoV-2. Results:...
Summary Introduction Changes in the magnitude of efficacy throughout 26 weeks atomoxetine treatment, along with impact dosing, were evaluated adults ADHD from two randomized, double‐blind, placebo‐controlled studies. Aims Pooled placebo (n = 485) and 518) patients, dosed 25, 40, 60, 80 (target dose), or 100 mg daily, assessed. Change baseline Conners’ Adult Rating Scale–Investigator Rated Scale: Screening Version (CAARS) total symptoms score Investigator Symptom Scale (AISRS) analyzed using...
Abstract Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have favorable safety profile and be effective for early treatment high-risk COVID-19 patients. The COMET-TAIL phase 3 study evaluated sotrovimab administered intravenously (IV) or intramuscularly (IM) participants with mild moderate who are at high risk disease progression. Methods Between June August 2021, 973 were...
The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high disease progression. Patient-reported outcomes are important capture symptom burden assess treatment effectiveness. This study investigated symptoms their impact over acute phase infection on versus placebo.Randomized (1:1), double-blind, multicenter, placebo-controlled, 2/3 in 57...
To analyze Clinical Global Impression-Severity (CGI-S) in ADHD patients treated with atomoxetine (ATX) monotherapy versus ATX combination therapy another ADHD-indicated medication.This was a 2-site retrospective observational chart review study of child and adult patients, not necessarily treatment naïve, but ≥50 days post baseline an endpoint assessment. adjust for measured confounders, (n = 77) 108) cohort comparisons were performed using propensity score stratification adjusted...